Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Helena Hohtari, MD, Shady Awad, MD, Olli Dufva, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Satu Mustjoki, MD PhD, Kimmo Porkka, MD PhD

Blood (2018) 132 (Supplement 1): 3975.

https://doi.org/10.1182/blood-2018-99-110610

Published: 2018

Journal Articles

Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 3938.

https://doi.org/10.1182/blood-2018-99-119880

Published: 2018

Journal Articles

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Markus Vaha-Koskela, PhD, Muhammad Ammad-ud-din, PhD, Kirsi Siivola, MSc, Tanja Ruokoranta, MSc, Laura Turunen, PhD, Kimmo Porkka, MD PhD, Pedro Marques Ramos, PhD, Celine Pallaud, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD

Blood (2018) 132 (Supplement 1): 2743.

https://doi.org/10.1182/blood-2018-99-116391

Published: 2018

Journal Articles

Predictive Response Biomarkers for BET Inhibitors in AML

Joseph J Saad, MSc, BSc, Juho Miettinen, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Samuli Eldfors, PhD, Mika Kontro, MD, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Jing Tang, PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2018-99-118363

Published: 2018

Journal Articles

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Brian S. White, PhD, Suleiman A. Khan, PhD, Muhammad Ammad-ud-din, PhD, Swapnil Potdar, MSc, Mike J Mason, PhD, Cristina E. Tognon, PhD, Brian J. Druker, MD, Caroline A Heckman, PhD, Olli Kallioniemi, MD PhD, Stephen E Kurtz, PhD, Kimmo Porkka, MD PhD, Jeffrey W. Tyner, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Justin Guinney, PhD

Blood (2018) 132 (Supplement 1): 2763.

https://doi.org/10.1182/blood-2018-99-111916

Published: 2018

Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 264.

https://doi.org/10.1182/blood-2018-99-118242

Published: 2018

Journal Articles

Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity

Mahesh Tambe, PhD, Ella Karjalainen, MSc, Markus Vaha-Koskela, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Krister Wennerberg, PhD

Blood (2018) 132 (Supplement 1): 2210.

https://doi.org/10.1182/blood-2018-99-118289

Published: 2018

Journal Articles

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199)

Ralf Buettner, PhD, Ching-Cheng Chen, PhD, Bijender Kumar, PhD, Corey Morales, BA, BS, Lisa S Chen, PhD, Krister Wennerberg, PhD, Ryan Thompson, MS, Tea Pemovska, MSc, Ling Li, PhD, Bin Zhang, PhD, Claudia Kowolik, PhD, Mika Kontro, MD, Calum Leitch, MD, David Horne, PhD, Joycelynne Palmer, PhD, Varsha Gandhi, PhD, Guido Marcucci, MD, Vinod Pullarkat, MD, Steven T. Rosen, MD

Blood (2016) 128 (22): 2758.

https://doi.org/10.1182/blood.V128.22.2758.2758

Published: 2016

Journal Articles

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth Via Novel RNA- and ATP-Directed Mechanisms: A Novel Therapeutic Approach for AML

Ralf Buettner, PhD, Ching-Cheng Chen, PhD, Bijender Kumar, PhD, Lisa S Chen, PhD, Krister Wennerberg, PhD, Ryan Thompson, MS, Tea Pemovska, MSc, Ling Li, PhD, Varsha Gandhi, PhD, Guido Marcucci, MD, Vinod Pullarkat, MD, Steven T. Rosen, MD

Blood (2015) 126 (23): 792.

https://doi.org/10.1182/blood.V126.23.792.792

Published: 2015

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

Mika Kontro, MD, Samuli Eldfors, MSc, Muntasir Mamun Majumder, MSc,MPharm, Alun Parsons, MSc, Tea Pemovska, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD

Blood (2015) 126 (23): 2462.

https://doi.org/10.1182/blood.V126.23.2462.2462

Published: 2015

Journal Articles

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

Muntasir Mamun Majumder, MSc,BPharm, Raija Silvennoinen, MD, Pekka Antilla, David Tamborero, Samuli Eldfors, MSc, Riikka Karjalainen, MSc, Heikki Kuusanmäki, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Marjanna Säily, Bhagwan Yadav, MSc, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2046.

https://doi.org/10.1182/blood.V124.21.2046.2046

Published: 2014

Journal Articles

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Paavo Pietarinen, MSc, Tea Pemovska, MSc, Emma I Andersson, MSc, Perttu Koskenvesa, MD, Mika Kontro, MD, Swapnil Potdar, MSc, John Patrick Mpindi, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD

Blood (2014) 124 (21): 3139.

https://doi.org/10.1182/blood.V124.21.3139.3139

Published: 2014

Journal Articles

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Muntasir Mamun Majumder, MSc, David Tamborero, PhD, Bhagwan Yadav, MSc, Mika Kontro, MD, Bjørn Gjertsen, MD PhD, Alun Parsons, MSc, Minna Suvela, BSc, Tero Aittokallio, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 3505.

https://doi.org/10.1182/blood.V124.21.3505.3505

Published: 2014

Journal Articles

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Leopold Sellner, MD, Malgorzata Oles, Tea Pemovska, MSc, Paavo Pietarinen, MSc, Anneli Lauhio, MD, Katarzyna Tomska, Carlos Cuesta-Mateos, MD PhD, Edgar Faber, Tim H. Brummendorf, MD PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD, Wolfgang Huber, PhD, Krister Wennerberg, PhD, Thorsten Zenz, MD, Satu Mustjoki, MDPhD

Blood (2014) 124 (21): 917.

https://doi.org/10.1182/blood.V124.21.917.917

Published: 2014

Journal Articles

Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies

Heikki Kuusanmäki, MSc, Hanna Rajala, MD PhD, Arjan van Adrichem, Muntasir Mamun Majumder, MSc,BPharm, Emma I Andersson, MSc, Krister Wennerberg, PhD, Satu Mustjoki, MDPhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 1771.

https://doi.org/10.1182/blood.V124.21.1771.1771

Published: 2014

Journal Articles

Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse

Naga Poojitha Ojamies, MSc, Mika Kontro, MD, Maija Wolf, PhD, Henrik Edgren, PhD, Pekka Ellonen, MSc, Sonja Lagström, MSc, Tiina Hannunen, MSc, Tea Pemovska, MSc, Henrikki Almusa, MSc, Maija Lepistö, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2014) 124 (21): 1022.

https://doi.org/10.1182/blood.V124.21.1022.1022

Published: 2014

Journal Articles

AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines

Disha Malani, MSc, Astrid Murumägi, PhD, Bhagwan Yadav, MSc, Tea Pemovska, MSc, John Patrick Mpindi, MSc, Mika Kontro, MD, Tero Aittokallio, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Krister Wennerberg, PhD, Maija Wolf, PhD, Olli Kallioniemi, MD PhD

Blood (2014) 124 (21): 2163.

https://doi.org/10.1182/blood.V124.21.2163.2163

Published: 2014

Journal Articles

High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1 -Positive Leukemia

Paavo Pietarinen, MSc, Muntasir Mamun Majumder, MSc, Disha Malani, MSc, Astrid Murumägi, PhD, Tea Pemovska, MSc, Perttu Koskenvesa, MD, Olli Kallioniemi, MD, PhD, Krister Wennerberg, PhD, Caroline A. Heckman, PhD, Satu Mustjoki, MD, PhD, Kimmo Porkka, MD, PhD

Blood (2013) 122 (21): 2719.

https://doi.org/10.1182/blood.V122.21.2719.2719

Published: 2013

Journal Articles

Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Bhagwan Yadav, MSc, Muntasir Mamun Majumder, MSc, Mika Kontro, MD, Kimmo Porkka, MD, PhD, Olli Kallioniemi, MD, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2013) 122 (21): 1668.

https://doi.org/10.1182/blood.V122.21.1668.1668

Published: 2013

NARROW

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML)

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Predictive Response Biomarkers for BET Inhibitors in AML

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199)

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth Via Novel RNA- and ATP-Directed Mechanisms: A Novel Therapeutic Approach for AML

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies

Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse

AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines

High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1 -Positive Leukemia

Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only